SeaStar Medical Holding Co. (NASDAQ:ICU) Short Interest Down 18.7% in February

Posted by Casey Walker on Mar 5th, 2025

SeaStar Medical Holding Co. (NASDAQ:ICU – Get Free Report) was the target of a large drop in short interest during the month of February. As of February 15th, there was short interest totalling 300,900 shares, a drop of 18.7% from the January 31st total of 370,200 shares. Based on an average daily volume of 423,600 shares, the short-interest ratio is presently 0.7 days. Currently, 3.6% of the company’s stock are short sold.

Institutional Investors Weigh In On SeaStar Medical

A hedge fund recently raised its stake in SeaStar Medical stock. Geode Capital Management LLC boosted its stake in SeaStar Medical Holding Co. (NASDAQ:ICU – Free Report) by 14.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 45,430 shares of the company’s stock after purchasing an additional 5,618 shares during the period. Geode Capital Management LLC owned approximately 1.02% of SeaStar Medical worth $88,000 at the end of the most recent quarter. Institutional investors and hedge funds own 1.69% of the company’s stock.

SeaStar Medical Stock Up 0.6 %

Shares of SeaStar Medical stock traded up $0.01 on Wednesday, reaching $1.71. The company’s stock had a trading volume of 96,115 shares, compared to its average volume of 494,648. The company has a market capitalization of $7.63 million, a price-to-earnings ratio of -0.15 and a beta of -1.02. SeaStar Medical has a 52 week low of $1.50 and a 52 week high of $27.50. The firm’s fifty day simple moving average is $1.85 and its two-hundred day simple moving average is $3.02.

About SeaStar Medical

(Get Free Report)

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome.